# Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/oral-fingolimod-in-primary-progressive-multiple-sclerosis-informs-a-phase-3/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Fred Lublin,David H. Miller,Mark S. Freedman,Bruce Cree,Jerry S. Wolinsky,Howard L. Weiner,Catherine Lubetzki,Hans‐Peter Hartung,Xavier Montalbán,Bernard M.J. Uitdehaag,Martin Merschhemke,Bingbing Li,Norman Putzki,Fonda Liu,Dieter A. Häring,Ludwig Kappos |
| Citations | 452 |
| DOI | 10.1016/s0140-6736(15)01314-8 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://univoak.eu/islandora/object/islandora%3A63792 |
| OpenAlex ID | https://openalex.org/W2267348707 |
| PMID | 26827074 |
| Type | article |
| Year | 2016 |

## Paper authors

- [Catherine Lubetzki](https://scholariq.org/researchers/catherine-lubetzki/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Sphingolipid Metabolism and Signaling](https://scholariq.org/topics/sphingolipid-metabolism-and-signaling/)

## Paper topics

- [Sphingolipid Metabolism and Signaling](https://scholariq.org/topics/sphingolipid-metabolism-and-signaling/)
- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.